Atypical response and progression patterns in advanced non-small cell lung cancer receiving immunochemotherapy or chemotherapy: A post hoc analysis of CHOICE-01
Therapeutic Advances in Medical Oncology · 2026-11 · 18
DOI: 10.1177/17588359261508786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 17.11.2026. Verfasst von Yuanyuan Yang und 15 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National High Level Hospital Clinical Research Funding.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Several atypical response and progression patterns have been recognized in advanced non-small cell lung cancer (NSCLC), yet their incidence, prognostic significance, and associated features remain poorly defined.
Objectives
To characterize the incidence, prognostic significance, clinical predictors, and exploratory genomic correlates of seven predefined atypical response and progression patterns among patients with advanced NSCLC receiving first-line immunochemotherapy or chemotherapy.
Design
Post hoc analysis of the randomized, double-blind, phase III CHOICE-01 trial.
Methods
A total of 465 patients with advanced NSCLC receiving toripalimab plus platinum-based chemotherapy (n = 309) or placebo plus chemotherapy (n = 156) were included. Seven predefined atypical response and progression patterns were systematically evaluated. Survival outcomes were assessed using Kaplan–Meier analyses and multivariable models. Clinicopathological characteristics, hematologic biomarkers, and baseline genomic profiling data were analyzed to identify clinical predictors and exploratory genomic correlates.
Results
Durable response (19.1% vs . 7.7%, P = 0.001) and dissociated response (16.8% vs . 10.3%, P = 0.05) occurred more frequently in the immunochemotherapy cohort. Durable response ( P < 0.0001) and delayed response ( P = 0.007) were associated with prolonged overall survival. Among patients with disease progression, fast progression was associated with worse survival ( P < 0.0001), whereas slow progression was associated with improved outcomes compared with others ( P = 0.0028). Multivariable analysis identified non-squamous histology and low neutrophil-to-lymphocyte ratio as independent predictors of durable response. Exploratory genomic analyses identified candidate genomic alterations associated with distinct response and progression patterns.
Conclusions
Predefined atypical response and progression patterns exhibit distinct clinical and prognostic characteristics in advanced NSCLC treated with immunochemotherapy or chemotherapy. These findings highlight the heterogeneity of treatment response patterns and provide hypotheses for future biomarker studies.
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National High Level Hospital Clinical Research Funding
- CAMS Key discipline Fund project of Medical Oncology
- Beijing Xisike Clinical Oncology Research Foundation
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Yang, Y., Bai, H., Wang, Z., Duan, J., Shi, Y., Li, C., Xu, J., Fei, K., Wan, R., Sun, B., Zhao, J., Liu, L., Lin, Y., Zeng, W., Zhong, J., & Wang, J. (2026). Atypical response and progression patterns in advanced non-small cell lung cancer receiving immunochemotherapy or chemotherapy: A post hoc analysis of CHOICE-01. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261508786
Vancouver
Yang Y, Bai H, Wang Z, Duan J, Shi Y, Li C, et al. Atypical response and progression patterns in advanced non-small cell lung cancer receiving immunochemotherapy or chemotherapy: A post hoc analysis of CHOICE-01. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261508786
BibTeX
@article{Yang2026,
author = {Yang, Yuanyuan and Bai, Hua and Wang, Zhijie and Duan, Jianchun and Shi, Yezhen and Li, Chengcheng and Xu, Jiachen and Fei, Kailun and Wan, Rui and Sun, Boyang and Zhao, Jie and Liu, Lihui and Lin, Yiwen and Zeng, Wenjuan and Zhong, Jia and Wang, Jie},
title = {Atypical response and progression patterns in advanced non-small cell lung cancer receiving immunochemotherapy or chemotherapy: A post hoc analysis of CHOICE-01},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261508786}
}
EUVIMED